GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » Gross Profit

Getein Biotech (SHSE:603387) Gross Profit : ¥879 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Getein Biotech Gross Profit?

Getein Biotech's gross profit for the three months ended in Jun. 2024 was ¥198 Mil. Getein Biotech's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was ¥879 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Getein Biotech's gross profit for the three months ended in Jun. 2024 was ¥198 Mil. Getein Biotech's Revenue for the three months ended in Jun. 2024 was ¥296 Mil. Therefore, Getein Biotech's Gross Margin % for the quarter that ended in Jun. 2024 was 66.85%.

Getein Biotech had a gross margin of 66.85% for the quarter that ended in Jun. 2024 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Getein Biotech was 83.83%. The lowest was 63.03%. And the median was 75.85%.

Warning Sign:

Getein Biotech Inc gross margin has been in long-term decline. The average rate of decline per year is -3.1%.


Getein Biotech Gross Profit Historical Data

The historical data trend for Getein Biotech's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getein Biotech Gross Profit Chart

Getein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 704.79 708.04 919.24 1,185.47 923.10

Getein Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 197.05 202.44 248.36 229.85 197.93

Competitive Comparison of Getein Biotech's Gross Profit

For the Medical Devices subindustry, Getein Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getein Biotech's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Gross Profit distribution charts can be found below:

* The bar in red indicates where Getein Biotech's Gross Profit falls into.



Getein Biotech Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Getein Biotech's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1369.162 - 446.065
=923

Getein Biotech's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=296.085 - 98.155
=198

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥879 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Getein Biotech's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=198 / 296.085
=66.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Getein Biotech  (SHSE:603387) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Getein Biotech had a gross margin of 66.85% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Getein Biotech Gross Profit Related Terms

Thank you for viewing the detailed overview of Getein Biotech's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Getein Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
Executives
Su En Kui Director
Yan Bin Director
Kong Ting Ting Director
Xu Xing De Director
Su En Ben Director

Getein Biotech Headlines

No Headlines